In our dual-center case series, we found that extreme response in mCRPC patients treated with [177Lu]Lu-PSMA PRLT was independent of tumor site, pattern of disease, radiotherapeutical uptake, baseline PSA levels, previous treatments, age, race/nationality, Gleason score, and BRCA sequencing status. Here, FOLH1 is linked to neoplasm.